Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer

British Journal of Cancer

Volumn 95, Issue 3, 2006, Pages 347-354

  Radke, I ^a   Gotte M ^a   Kersting, C ^b   Mattsson, B ^a   Kiesel, L ^a   Wulfing P ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Breast cancer; Immunohistochemistry; PRL 3; Prognostic factor; PTP4A3

Indexed keywords

MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE PRL 1; PROTEIN TYROSINE PHOSPHATASE PRL 2; PROTEIN TYROSINE PHOSPHATASE PRL 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA IN SITU; CLINICAL FEATURE; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN TYROSINE PHOSPHATASES; PROTEIN-TYROSINE-PHOSPHATASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 33746904684     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603261     Document Type: Article

References (44)

1. Alberts B (2002) Molecular Biology of the Cell. Garland Science: New York
2. Ambler CA, Schmunk G, Bautch VL (2003) Stem cell-derived endothelial cells/progenitors migrate and pattern in the embryo using the VEGF signaling pathway. Dev Biol 257: 205-219
3. Bardelli A, Saha S, Sager J, Romans K, Xin B, Markowitz S, Lengauer C, Velculescu V, Kinzler K, Vogelstein B (2003) PRL-3 expression in metastatic cancers. Clin Cancer Res 9: 5607-5615
4. Cates CA, Michael R, Stayrook K, Harvey KA, Burke Y, Randall SK, Crowell PL, Crowell DN (1996) Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett 110: 49-55
5. Chia S, Speers C, Bryce C, Hayes MM, Olivotto I (2004) Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22: 1630-1637
6. De Jong JS, Van Diest PJ, Van Der Valk P, Baak J (2001) Expression of growth factors, growth factor receptors and apoptosis related proteins in invasive breast cancer: relation to apoptotic rate. Breast Cancer Res Treat 66: 201-208
7. Diamond R, Cressman D, Laz T, Abrams CS, Taub R (1994) PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 14: 3752-3762
8. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
9. Elston CW, Ellis I (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19;403-410.
10. Histopathology 41: 151
11. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31
12. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235: 442-447
13. Gasparini G (2001) Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37: 97-114
14. Goldhirsch A, Glick JH, Gelber R, Coates AS, Thurlimann B, Senn H (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569-1583
15. Guo K, Li J, Tang J, Koh V, Gan B, Zeng Q (2004) Catalytic domain of PRL-3 plays an essential role in tumor metastasis: Formation of PRL-3 Tumors inside the blood vessels. Cancer Biol Ther 3: 945-951
16. Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100: 57-70
17. Holland R, Peterse J, Millis RR, Eusebi V, Faverly D, Van De Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180
18. Kato H, Semba S, Miskad U, Seo Y, Kasuga M, Yokozaki H (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10: 7318-7328
19. McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9: 713-725
20. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2): 67-72
21. Miskad U, Semba S, Kato H, Yokozaki H (2004) Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71: 176-184
22. Mohn K, Laz T, Hsu J, Melby A, Bravo R, Taub R (1991) The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. Mol Cell Biol 11: 381-390
23. Montagna M, Serova O, Sylla B, Feunteun J, Lenoir GM (1995) A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. Hum Genet 96: 532-538
24. Morabito A, Sarmiento R, Bonginelli P, Gasparini G (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hematol 49: 91-107
25. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116
26. Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, Kaider A, Leodolter S, Kainz C, Zeillinger R (1997) Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74: 455-458
27. Parker BS, Argani P, Cook B, Liangfeng H, Chartrand S, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, Nacht M, Teicher B, Klinger K, Sukumar S, Madden SL (2004) Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 64: 7857-7866
28. Pathak M, Dhawan D, Lindner DJ, Borden E, Farver C, Yi T (2002) Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 1: 1255-1264
29. Peng L, Ning J, Meng L, Shou C (2004) The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 130: 521-526
30. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A, Broggini M (2005) PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 11: 6835-6839
31. Ross J, Fletcher J (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428
32. Rouleau C, Roy A, St Martin T, Dufault M, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher B (2006) Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Mol Cancer Ther 5: 219-229
33. Samrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York
34. Sebti S, Der C (2003) Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3: 945-951
35. Sonntag B, Gotte M, Wülfing P, Schuring A, Kiesel L, Greb R (2005) Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 84(Suppl 2): 1173-1179
36. Stephens B, Han H, Gokhale V, Von Hoff DD (2005) PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 4: 1653-1661
37. Wang J, Kirby CE, Herbst R (2002) The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem 277: 46659-46668
38. Wülfing P, Diallo R, Muller C, Wülfing C, Poremba C, Heinecke A, Rody A, Greb R, Bocker W, Kiesel L (2003) Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382
39. Wülfing P, Gotte M, Sonntag B, Kersting C, Schmidt H, Wülfing C, Buerger H, Greb R, Bocker W, Kiesel L (2005b) Overexpression of Endothelin-A-receptor in breast cancer: Regulation by estradiol and cobalt-chloride induced hypoxia. Int J Oncol 26: 951-960
40. Wülfing P, Kersting C, Buerger H, Mattsson B, Mesters R, Gustmann C, Hinrichs B, Tio J, Bocker W, Kiesel L (2005a) Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92: 1720-1728
41. Wülfing P, Kersting C, Tio J, Fischer R, Wülfing C, Poremba C, Diallo R, Bocker W, Kiesel L (2004) Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 10: 2393-2400
42. Yoshiji H, Gomez D, Shibuya M, Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013-2016
43. Zeng Q, Dong J, Guo K, Li J, Tan H, Koh V, Pallen C, Manser E, Hong W (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63: 2716-2722
44. Zeng Q, Hong W, Tan Y (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 244: 421-427